Gambia

PATH is on the front lines of an effort to defeat meningitis by 2030.

Results from a Phase 2 clinical study of a pentavalent meningococcal meningitis vaccine designed for use in the African meningitis belt demonstrate the vaccine candidate to be safe, well-tolerated, and capable of producing strong immune responses to all five serogroups.

This brief summarizes the experience and capabilities of the PATH Cervical Cancer Team. For decades, PATH has been at the forefront of evidence-based strategies from HPV vaccine research and delivery to cervical cancer screening and treatment to ensure we best meet the needs and realities of these countries for the greatest health impact.

Access to screening and vaccination could significantly reduce HPV-related cancers in a generation. One country recently took an important step to protect their girls from HPV infection and cervical cancer.

This fact sheet provides an overview of the MVP Access Program, an initiative that grants researchers access to data sets and frozen serum samples collected during the MenAfriVac ® clinical studies in Africa. The fact sheet outlines MenAfriVac's ® development history, qualified uses of data, and how to request data and/or serum access.

Perspectives from The Gambia’s immunization program manager

Two clinicians reflect on evaluating early vaccines in The Gambia

Perspectives from a mom, an immunization manager, and clinical investigators.

One mother’s story about enrolling her child in a vaccine trial.

PATH and its partners have been conducting clinical trials to evaluate a pneumococcal vaccine designed to meet needs in low-resource countries.